Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“The treatment landscape for HR+/HER2− metastatic breast cancer is evolving rapidly.
With biomarker-driven therapies targeting ESR1, PIK3CA, BRCA, and the growing role of next-generation antibody-drug conjugates such as T-DXd, Dato-DXd, and sacituzumab govitecan, patients now have more effective and personalized options than ever before.”
Other articles about breast cancer on OncoDaily.